49
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Central Role for GRB10 in Regulation of Islet Function in Man

      research-article
      1 , 2 , 3 , 4 , 2 , 5 , 4 , 4 , 4 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 1 , 2 , 13 , 14 , 15 , 16 , 17 , 18 , 18 , 18 , 19 , 20 , 4 , 4 , 21 , 4 , 4 , 6 , 7 , 2 , 22 , 4 , 4 , 23 , 17 , 24 , 25 , 6 , 7 , 26 , 27 , 28 , 29 , 30 , 31 , 14 , 12 , 12 , 32 , 16 , 33 , 16 , 28 , 12 , 34 , 35 , 26 , 36 , 37 , 12 , 34 , 35 , 37 , 38 , 11 , 14 , 3 , 6 , 7 , 39 , 16 , 40 , 41 , 21 , 34 , 35 , 2 , 10 , 1 , 2 , 42 , 18 , 43 , 18 , 43 , 11 , 4 , 26 , * , 4 , 44 , *
      PLoS Genetics
      Public Library of Science

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Variants in the growth factor receptor-bound protein 10 ( GRB10) gene were in a GWAS meta-analysis associated with reduced glucose-stimulated insulin secretion and increased risk of type 2 diabetes (T2D) if inherited from the father, but inexplicably reduced fasting glucose when inherited from the mother. GRB10 is a negative regulator of insulin signaling and imprinted in a parent-of-origin fashion in different tissues. GRB10 knock-down in human pancreatic islets showed reduced insulin and glucagon secretion, which together with changes in insulin sensitivity may explain the paradoxical reduction of glucose despite a decrease in insulin secretion. Together, these findings suggest that tissue-specific methylation and possibly imprinting of GRB10 can influence glucose metabolism and contribute to T2D pathogenesis. The data also emphasize the need in genetic studies to consider whether risk alleles are inherited from the mother or the father.

          Author Summary

          In this paper, we report the first large genome-wide association study in man for glucose-stimulated insulin secretion (GSIS) indices during an oral glucose tolerance test. We identify seven genetic loci and provide effects on GSIS for all previously reported glycemic traits and obesity genetic loci in a large-scale sample. We observe paradoxical effects of genetic variants in the growth factor receptor-bound protein 10 ( GRB10) gene yielding both reduced GSIS and reduced fasting plasma glucose concentrations, specifically showing a parent-of-origin effect of GRB10 on lower fasting plasma glucose and enhanced insulin sensitivity for maternal and elevated glucose and decreased insulin sensitivity for paternal transmissions of the risk allele. We also observe tissue-specific differences in DNA methylation and allelic imbalance in expression of GRB10 in human pancreatic islets. We further disrupt GRB10 by shRNA in human islets, showing reduction of both insulin and glucagon expression and secretion. In conclusion, we provide evidence for complex regulation of GRB10 in human islets. Our data suggest that tissue-specific methylation and imprinting of GRB10 can influence glucose metabolism and contribute to T2D pathogenesis. The data also emphasize the need in genetic studies to consider whether risk alleles are inherited from the mother or the father.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          A genome-wide association study identifies novel risk loci for type 2 diabetes.

          Type 2 diabetes mellitus results from the interaction of environmental factors with a combination of genetic variants, most of which were hitherto unknown. A systematic search for these variants was recently made possible by the development of high-density arrays that permit the genotyping of hundreds of thousands of polymorphisms. We tested 392,935 single-nucleotide polymorphisms in a French case-control cohort. Markers with the most significant difference in genotype frequencies between cases of type 2 diabetes and controls were fast-tracked for testing in a second cohort. This identified four loci containing variants that confer type 2 diabetes risk, in addition to confirming the known association with the TCF7L2 gene. These loci include a non-synonymous polymorphism in the zinc transporter SLC30A8, which is expressed exclusively in insulin-producing beta-cells, and two linkage disequilibrium blocks that contain genes potentially involved in beta-cell development or function (IDE-KIF11-HHEX and EXT2-ALX4). These associations explain a substantial portion of disease risk and constitute proof of principle for the genome-wide approach to the elucidation of complex genetic traits.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis.

            By combining genome-wide association data from 8,130 individuals with type 2 diabetes (T2D) and 38,987 controls of European descent and following up previously unidentified meta-analysis signals in a further 34,412 cases and 59,925 controls, we identified 12 new T2D association signals with combined P<5x10(-8). These include a second independent signal at the KCNQ1 locus; the first report, to our knowledge, of an X-chromosomal association (near DUSP9); and a further instance of overlap between loci implicated in monogenic and multifactorial forms of diabetes (at HNF1A). The identified loci affect both beta-cell function and insulin action, and, overall, T2D association signals show evidence of enrichment for genes involved in cell cycle regulation. We also show that a high proportion of T2D susceptibility loci harbor independent association signals influencing apparently unrelated complex traits.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genotype imputation.

              Genotype imputation is now an essential tool in the analysis of genome-wide association scans. This technique allows geneticists to accurately evaluate the evidence for association at genetic markers that are not directly genotyped. Genotype imputation is particularly useful for combining results across studies that rely on different genotyping platforms but also increases the power of individual scans. Here, we review the history and theoretical underpinnings of the technique. To illustrate performance of the approach, we summarize results from several gene mapping studies. Finally, we preview the role of genotype imputation in an era when whole genome resequencing is becoming increasingly common.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Genet
                PLoS Genet
                plos
                plosgen
                PLoS Genetics
                Public Library of Science (San Francisco, USA )
                1553-7390
                1553-7404
                April 2014
                3 April 2014
                : 10
                : 4
                : e1004235
                Affiliations
                [1 ]Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
                [2 ]Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
                [3 ]Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, United Kingdom
                [4 ]Department of Clinical Science, Diabetes & Endocrinology, Lund University Diabetes Centre, Malmö, Sweden
                [5 ]Estonian Genome Center, University of Tartu, Tartu, Estonia
                [6 ]University of Lille Nord de France, Lille, France
                [7 ]CNRS UMR8199, Institut Pasteur de Lille, Lille, France
                [8 ]INSERM U970, Paris Cardiovascular Research Center PARCC, Paris, France
                [9 ]Department of Clinical Science, Neuroendocrine Cell Biology, Lund University Diabetes Centre, Malmö, Sweden
                [10 ]Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
                [11 ]Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
                [12 ]MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom
                [13 ]MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom
                [14 ]Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom
                [15 ]Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland
                [16 ]Folkhälsan Research Centre, Helsinki, Finland
                [17 ]Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America
                [18 ]Division of Endocrinology Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
                [19 ]Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
                [20 ]Department of Mathematics, Åbo Akademi University, Turku, Finland
                [21 ]Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University, CRC, Scania University Hospital, Malmö, Sweden
                [22 ]Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland
                [23 ]Department of Pharmacology and Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America
                [24 ]INSERM - Institut de Santé Publique, Paris, France
                [25 ]INSERM CIC EC 05, Hôpital Robert Debré, Paris, France
                [26 ]Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
                [27 ]Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom
                [28 ]Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
                [29 ]Program in Medical and Population Genetics and Genetics Analysis Platform, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusettes, United States of America
                [30 ]Molecular Medicine, Department of Medical Sciences, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
                [31 ]CNR Institute of Biomedical Engineering, Padova, Italy
                [32 ]Department of Clinical Science, Internal Medicine, Skåne University Hospital Malmö, Malmö, Sweden
                [33 ]Department of Social Service and Health Care, Jakobstad, Finland
                [34 ]University of Leipzig, Department of Medicine, Leipzig, Germany
                [35 ]University of Leipzig, IFB Adiposity Diseases, Leipzig, Germany
                [36 ]Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio, Finland
                [37 ]Kuopio Research Institute of Exercise Medicine, Kuopio, Finland
                [38 ]Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland
                [39 ]Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
                [40 ]Helsinki University, Department of General Practice and Primary Health Care, Helsinki, Finland
                [41 ]Helsinki University Central Hospital, Unit of General Practice, Helsinki, Finland
                [42 ]Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kindom
                [43 ]Baltimore Geriatric Research, Education and Clinical Center, Baltimore, Maryland, United States of America
                [44 ]Steno Diabetes Center A/S, Gentofte, Denmark
                Dartmouth College, United States of America
                Author notes

                I have read the journal's policy and we have the following conflicts: VLy declares that Steno Diabetes Center is owned by Novonordisk, PK is funded by Boehringer Ingelheim Foundation, TF received payment for lectures from MSD (Merck), AM is a consultant for Eli Lilly and Poxel and has received grants from Eli Lilly and Boehringer Ingelheim, BI has received payment for lectures from Boehringer Ingelheim, MSD, Novo Nordisk Farma and AstraZeneca, LG has been a consultant for and served on advisory boards for Sanofi-Aventis, GSK, Novartis, Merck, Tethys Bioscience and Xoma, and received lecture fees from Lilly and Novartis. We confirm that these affiliations do not alter the adherence to all the PLOS Genetics policies on sharing data and materials.

                Conceived and designed the experiments: IP WP RM RPB SAS PO NW TD CLi KDS ML LG VLy. Performed the experiments: WP RM RPB SAS PO NW TD KH. Analyzed the data: IP WP RM RPB SAS PA PO NBN NW TF AS AB VLa CO WX JLa AUJ YCC JLi JRO PAB JF SA TD EA JT CLe AK OH KH BFV HMK CLM VV MNW RJL KKO CLa AT RR JK CLi PK KDS VLy. Contributed reagents/materials/analysis tools: SAS PA PO NW AP ACS AM PN BI TT NJW MS EW TAL TMF PF MW JGE CLi EI ARS KDS ML LG VLy. Wrote the paper: IP WP RM RPB PO NW AB MIM CLi LG VLy.

                Article
                PGENETICS-D-13-01536
                10.1371/journal.pgen.1004235
                3974640
                24699409
                f0738edb-3700-4555-947c-66e22ea3a46c
                Copyright @ 2014

                This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

                History
                : 8 June 2013
                : 20 January 2014
                Page count
                Pages: 13
                Funding
                Studies at LUDC in Malmö (DGI, BPS, PPP, MPP and human islets) were supported by grants from the Swedish Research Council (SFO EXODIAB: Dnr 2009-1039), Linnaeus grant (LUDC Dnr 349-2008-6589), project grants to VLy, LG, NW, and CLi, and financial support from the Swedish Research Council (Dnr 521-2010-3490, Dnr 521-2010-3490, Dnr 521-2010-3490, Dnr 521-2007-4037, Dnr 521-2008-2974, ANDIS Dnr 825-2010-5983), the Knut & Alice Wallenberg foundation (KAW 2009.0243), the Torsten och Ragnar Söderbergs Stiftelser (MT33/09), the Inga Britt och Arne Lundberg's Research Foundation (grant nr. 359), the Heart and Lung Foundation, the Novo Nordisk foundation, Diabetes Research & Wellness, Sydvästra Skånes Diabetesförening. The PPP-Botnia study was supported by grants from the Sigrid Juselius Foundation, the Finnish Diabetes Research Society, the Signe and Ane Gyllenberg Foundation, the Swedish Cultural Foundation in Finland, the Ollqvist Foundation, the Foundation for Life and Health in Finland, Jakobstad Hospital, the Medical Society of Finland, the Närpes Research Foundation and the Vasa and Närpes Health centers. The MPP study was supported by a grant from the Swedish Heart and Lung Foundation, the E. Lundström Foundation and from the Region Skåne County Council funds. The RISC Study was supported by European Union grant QLG1-CT-2001-01252 and AstraZeneca. The Amish Family Diabetes Study was supported by NIH research grants R01 DK54261, R01 DK68495, U01 HL84756, the University of Maryland General Clinical Research Center (M01 RR16500), Hopkins Bayview General Clinical Research Center (M01 RR02719), the Mid-Atlantic Nutrition Obesity Research Center (P30 DK072488), the Baltimore Diabetes Research and Training Center grant (P60 DK79637), the Baltimore Veterans Administration Geriatric Research and Education Clinical Center, and by USDA NIFA NRI Competitive Grant 2007-35205-17883. The DR's EXTRA Study was supported by grants to RR by the Ministry of Education and Culture of Finland (627;2004-2011), Academy of Finland (102318; 123885), Kuopio University Hospital, Finnish Diabetes Association, Finnish Heart Association, Päivikki and Sakari Sohlberg Foundation and by grants from European Commission FP6 Integrated Project (EXGENESIS), LSHM-CT-2004-005272, City of Kuopio and Social Insurance Institution of Finland (4/26/2010). The METSIM Study was supported by grants from the Academy of Finland (141069, 141226), Diabetes Research Foundation, and Sigrid Juselius Foundation. The ULSAM project was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Foundation for Strategic Research, the Royal Swedish Academy of Sciences, Swedish Diabetes Foundation, Swedish Society of Medicine, and Novo Nordisk Foundation. Part of the genotyping in ULSAM for this project was supported through the ENGAGE (European Network for Genetic and Genomic Epidemiology) Consortium, which is funded through the European Community's Seventh Framework Programme (HEALTH-F4-2007- 201413). The SNP & SEQ Technology Platform in Uppsala was supported by Science for Life Laboratory and the Swedish Research Council for Infrastructures (RFI). The Sorbs work was supported by grants from the German Research Council (DFG - SFB 1052 “Obesity mechanisms”; A01, B03, C01), from the German Diabetes Association and from the DHFD (Diabetes Hilfs- und Forschungsfonds Deutschland). IFB Adiposity Diseases is supported by the Federal Ministry of Education and Research (BMBF), Germany, FKZ: 01EO1001. PK is funded by Boehringer Ingelheim Foundation. RM acknowledges financial support from the European Commission under a Marie Curie Intra-European Fellowship, EFSD New Horizons grant, and Development Fund of the University of Tartu, in the frame of the Centre of Transitional Genomics (grant SP1GVARENG) and by Estonian Government (grant #SF0180142s08). The research of IP and VLa was funded in part through the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-2007-201413. Helsinki Birth Cohort Study (HBCS) has been supported by grants from the Academy of Finland (Grant No. 120386 and 125876 to JGE), the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, Liv och Hälsa, the Wellcome Trust (Grant No. 89061/Z/09/Z and 089062/Z/09/Z), Samfundet Folkhälsan, Finska Läkaresällskapet, the Signe and Ane Gyllenberg foundation, the Univeristy of Helsinki, Ministry of Education, Ahokas Foundation, Emil Aaltonen Foundation, European Science Foundation (EUROSTRESS), Juho Vainio Foundation, and Wellcome Trust (grant WT089062). MIM is a Wellcome Trust Senior Investigator, and an NIHR Senior Investigator, and has also received funding from EU Framework 7: ENGAGE Consortium HEALTH-F4-2007-201413, Wellcome Trust: 083270, 090367, 090532, 098381, Medical Research Council: G0601261 and Diabetes UK: RD08/0003704. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology and life sciences
                Anatomy
                Endocrine System
                Endocrine Cells
                Biochemistry
                Hormones
                Insulin
                Computational Biology
                Genome Analysis
                Genome-Wide Association Studies
                Genetics
                Epigenetics
                RNA interference
                Gene expression
                DNA transcription
                Heredity
                Complex Traits
                Quantitative Traits
                Trait Loci
                Gene Function
                Genetics of Disease
                Genomics
                Human Genetics
                Physiology
                Endocrine Physiology
                Medicine and Health Sciences
                Endocrinology
                Diabetic Endocrinology
                Metabolic Disorders
                Diabetes Mellitus
                Type 2 Diabetes

                Genetics
                Genetics

                Comments

                Comment on this article